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Activation of PAR2 by tissue factor 
induces the release of the PTEN 
from MAGI proteins and regulates 
PTEN and Akt activities
Mohammad A. Mohammad1, John Greenman1, Anthony Maraveyas2 & Camille Ettelaie 1*
Tissue factor (TF) signalling has been associated with alterations in Akt activity influencing cellular 
survival and proliferation. TF is also shown to induce signalling through activation of the protease 
activated receptor (PAR)2. Seven cell lines were exposed to recombinant-TF (rec-TF), or activated 
using a PAR2-agonist peptide and the phosphorylation state of PTEN, and the activities of PTEN 
and Akt measured. Furthermore, by measuring the association of PTEN with MAGI proteins a 
mechanism for the induction of signalling by TF was proposed. Short term treatment of cells resulted 
in de-phosphorylation of PTEN, increased lipid-phosphatase activity and reduced Akt kinase activity 
in most of the cell lines examined. In contrast, continuous exposure to rec-TF up to 14 days, resulted 
in lower PTEN antigen levels, enhanced Akt activity and increased rate of cell proliferation. To explore 
the mechanism of activation of PTEN by TF, the association of "membrane-associated guanylate 
kinase-with inverted configuration" (MAGI)1–3 proteins with PTEN was assessed using the proximity 
ligation assay and by co-immunoprecipitation. The interaction of PTEN with all three MAGI proteins 
was transiently reduced following PAR2 activation and explains the changes in PTEN activity. Our data 
is first to show that PAR2 activation directly, or through exposure of cells to TF releases PTEN from 
MAGI proteins and is concurrent with increases in PTEN phosphatase activity. However, prolonged 
exposure to TF results in the reduction in PTEN antigen with concurrent increase in Akt activity which 
may explain the aberrant cell survival, proliferation and invasion associated with TF during chronic 
diseases.
Abbreviations
TF  Tissue factor
fVIIa/Xa  Factor VIIa/fXa
PTEN  Phosphatase and tensin homolog protein
PI3K  Phosphoinositol-3-kinase
PIP3  Phosphoinositol-3-phosphate
MAGI  Membrane-associated guanylate kinase-with inverted configuration
PAR2  Protease activated receptor 2
Tissue factor (TF) initiates the coagulation mechanism through formation of a complex with factor VIIa (fVIIa) 
which then activates factors X and  IX1,2. TF is present on the surface of cells and is also released within cell-
derived  microvesicles3–6. In addition to its procoagulant function, TF possesses signalling properties both 
in the cells expressing the protein, as well as on exposure of the recipient cells to exogenous TF-containing 
 microvesicles7,8. TF has been strongly associated with more aggressive cancer types and the link between TF 
and cellular survival, proliferation and migration has been  established9,10. A number of studies have reported 
the association of the Akt pathway with TF expression and/or the treatment of cells with fVIIa (or fVIIai)11–13 in 
cells which already express  TF11–16. Enhanced Akt activation following the incubation of TF-positive cells with 
fVIIa requires the proteolytic activity of  fVIIa11–15. However, differing reports attribute Akt activation to be both 
 dependent16–18 and independent of protease activated receptor (PAR) 2  signalling19,20. It has also been shown that 
fVIIa signalling suppresses Akt phosphorylation in a TF-cytoplasmic domain dependent  manner18. Furthermore, 
OPEN
1Biomedical Sciences, University of Hull, Cottingham Road, Hull HU6 7RX, UK. 2Division of Cancer-Hull York 
Medical School, University of Hull, Cottingham Road, Hull HU6 7RX, UK. *email: C.Ettelaie@hull.ac.uk
2
Vol:.(1234567890)
Scientific Reports |        (2020) 10:20908  | https://doi.org/10.1038/s41598-020-77963-6
www.nature.com/scientificreports/
work carried out in our  laboratory21 and reported by Aharon et al.7 has demonstrated that acute exposure of 
cells to TF, or inability to release excess  TF22,23 can induce cellular apoptosis. In addition, PAR2 signalling has 
been reported to  suppress18 or alternatively enhance PI3K/Akt  activation16,17 while conversely, Akt is reported 
to interfere with PAR2  signalling24.
Phosphatase and tensin homolog (PTEN) is a protein- and lipid-phosphatase which acts as one of the key 
regulators of the PI3K-Akt pathway and has been identified as a tumour suppressor. The loss of PTEN through 
mutational inactivation has been strongly associated with many  cancers25–28. These alterations have been identi-
fied as markers of the severity of the progression of  cancer29–32, as well as the aberrant formation of tissue and 
 tumourgenesis33,34. However, reductions in the levels of cellular PTEN are also known to alter the progression 
of a number of cancers and are detrimental in the pre-cancerous growth and tumourgenesis. Furthermore, 
mutational loss of the PTEN gene not only elevates the probability of carcinogenesis, but also has been associated 
with disorders including Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome which are characterised 
by the development of non-cancerous  tumours35–37. The impairment in PTEN activity due to either functional 
mutation or deletion has been reported to promote tumourgenesis in  breast38,  renal39,  prostate40, head and 
 neck41 and lung  cells42. Therefore, the non-mutagenic deregulation of PTEN is likely to be an important linkage 
between chronic inflammation and tumourgenesis. PTEN suppresses Akt activity by converting PI(3,4,5)P3 to 
PI(4,5)P2, preventing the localisation of Akt to the inner side of the plasma  membrane43–45. Consequently, PTEN 
has been classified as a key tumour-suppressor and the loss of PTEN is known to significantly influence cancer 
 progression29,46. The activity of PTEN is regulated through de-phosphorylation47,48 coupled with recruitment 
to the cell membrane which in turn enhances its lipid-phosphatase  function49,50. It has also been reported that 
the recruitment and activation of PTEN to the membrane is concurrent with binding to membrane-associated 
guanylate kinase with inverted configuration (MAGI)  proteins51–54.
To date, four MAGI proteins have been identified (MAGI1-3 and MAGIX). MAGI1-3 have been reported to 
be capable of binding  PTEN51–54 but at present, no evidence for the interaction between PTEN and MAGIX exists. 
The MAGI proteins contain a number of separate protein binding motifs including WW and PDZ domains, 
with the latter being involved in binding of MAGI to c-terminus of  PTEN54. MAGI proteins have been impli-
cated in the control of cell migration and invasion through altering the activity of PTEN and modulating Akt 
 signalling51–54. Moreover, it is known that the de-phosphorylation of PTEN also accelerates its degradation and 
can therefore moderate the total amount of PTEN within the  cell53.
In the current study, the influence of acute and prolonged exposure of a panel of seven cancer cell lines to 
exogenous recombinant TF, as well as PAR2 activation, on both PTEN and Akt activities, and cell proliferation 
was examined. In addition, a novel mechanism for the observed outcomes, involving MAGI proteins has been 
proposed.
Material and methods
Cell culture, cellular activation and determination of cell numbers. Seven cell lines were selected 
to include a range of TF and PAR2  expression55 and not on the basis of tissue of origin. Cells lines (ATCC, Ted-
dington, UK) MDA-MB-231 (breast cancer) and PANC-1 (pancreatic cancer) cells were cultured in DMEM; 
AsPC-1 (pancreatic cancer) and T47-D (breast cancer) lines were cultured in RPMI-1640; MCF-7 (breast can-
cer) and CaCo-2 (colorectal cancer) cells were cultured in EMEM and LoVo (colorectal cancer) cells were cul-
tured in Ham’s F-12K medium. All media were obtained from Lonza (Cambridge, UK) and contained foetal 
calf serum 10% (v/v). Cells (2 × 105) were seeded out into 12-well plates and activated either by the addition of 
recombinant TF (0–1300 pg/ml; Dade Behring, Deerfield, USA) or by incubation with PAR2-agonist peptide 
(PAR2-AP; SLIGKV; 20 µM) and incubated for durations stated in the results section. In some experiments 
selected cell lines were pre-incubated with a blocking antibody against PAR2 (SAM-11; 20 µg/ml; Santa Cruz 
Biotechnology Heidelberg, Germany). The reagents were previously determined to be free of endotoxin using 
the Limulus Amebocyte Lysate kit (LAL, Cambrex Bio Science, Wokingham, UK)56. This particular commer-
cial recombinant TF was used as an activating agent, because it is capable of acting as a co-factor for fVIIa for 
activating PAR2, but it lacks the cytoplasmic domain. Cell numbers were determined by crystal violet staining 
using a kit obtained from Active Motif (La Hulpe, Belgium) as previously described and  confirmed22,57. The cell 
numbers were interpreted from separate standard curve constructed for each cell line.
SDS-PAGE and western blot analysis. Cells were lysed in Laemmli’s buffer and were separated by 12% 
(w/v) SDS-PAGE58, transferred onto nitrocellulose membranes and then blocked with TBST (10 mM Tris–HCl 
pH 7.4, 150 mM NaCl, 0.05% Tween-20). Western blot analysis of PTEN phosphorylation in the samples was 
carried out using a rabbit anti-human phosphoSer380/Thr382/Thr383-PTEN (Cell Signalling Technologies/
New England Biolabs, Hitchin, UK) diluted 1:2000 (v/v) in TBST. Total PTEN was detected using a polyclonal 
rabbit anti-human PTEN antibody (Cell Signalling) diluted 1:2000 (v/v) in TBST. GAPDH was detected using 
a rabbit anti-human GAPDH polyclonal antibody (Santa Cruz Biotechnology, Heidelberg, Germany), diluted 
1:4000 (v/v) in TBST. The membranes were then washed with TBST and probed with a goat anti-rabbit alkaline 
phosphatase-conjugated antibody (Santa Cruz), diluted 1:4000 (v/v). Bands were then visualised using the West-
ern Blue stabilised alkaline phosphatase-substrate (Promega Corp., Southampton, UK), recorded and analysed 
using ImageJ program. On each occasion western blot membrane was cut into two and the higher molecular 
weight section was probed for PTEN or pPTEN, while the lower section was probed for GADPH. The numbers 
were normalised on all occasions.
Determination of the relative amount of PTEN mRNA by RT-PCR. Total RNA was isolated using 
the TRI-reagent system (Sigma Chemical Company, Poole, UK) from 2 × 105 cells and 100 ng of total RNA was 
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used for each reaction. The relative amounts of PTEN mRNA was determined using QuantiTect primer sets to 
detect PTEN and β-actin (Qiagen, Manchester, UK). The reaction was carried out at an annealing temperature 
of 60 °C for 1 min using the GoTaq 1-Step RT-qPCR System (Promega Corporation Ltd, Southampton, UK) on 
an iCycler thermal cycler (Bio-Rad, Hemel Hempstead, UK) for 40 cycles. Following amplification, the relative 
amounts of PTEN mRNA were determined using the  2−ΔΔCT method and PTEN:β-actin ratios were calculated.
Determination of PTEN antigen, PTEN lipid-phosphatase activity and Akt kinase activity 
using ELISA-based assay kits. Cells (2 × 105) were seeded out into 12-well plates and treated with rec-
TF or PAR2-AP as described above. The cells were then lysed in PhosphoSafe buffer (150 µl; Merck-Millipore, 
Watford, UK) containing 1% (v/v) protease inhibitor cocktail (Sigma). The protein concentration in the lysates 
was determined using the Bradford protein estimation assay and the amount of cellular PTEN was measured in 
lysates (adjusted to 50 µl) using the Human PTEN ELISA kit (Abcam, Cambridge, UK). The ability of PTEN to 
hydrolyse PIP3 to PIP2 was measured in cell lysates (6 µl) using a PTEN Activity ELISA kit (echelon Biosciences/
LuBioScience, Zurich, Switzerland). The activity of Akt was measured in the samples (30  µl) using the Akt 
Kinase activity assay kit (Enzo Life Sciences, Exeter, UK) according to manufacturer’s instructions.
Duolink proximity ligation (PLA) assay. The procedure was carried out using the Duolink reagents 
(Sigma) and adapted from that previously described in  detail59 with minor modifications. MDA-MB-231 cells 
 (103) were seeded out into 35 mm-glass based μ-dishes (InVitro Scientific/Cellvis, Sunnyvale, USA) and adapted 
to serum-free medium for 1 h prior to activation. Sets of cells were then incubated with PAR2-AP (20 μM) for 
up to 30 min and then fixed with 4% (v/v) paraformaldehyde for 15 min. The cells were then washed three times 
with PBS and permeabilised with Triton X-100 0.1% (v/v) in PBS, for 5 min. All samples were blocked with 
Duolink blocking buffer for 1 h and incubated overnight with combinations of antibodies as follows, at 4 °C. To 
examine the potential interactions between PTEN and MAGI1-3, a mouse anti-PTEN antibody (217702; 1 μg/
ml; R&D Systems) was used together with rabbit anti-MAGI1 antibody (H-70; 2  μg/ml; Santa Cruz), rabbit 
anti-MAGI2 antibody (C3; 1 μg/ml; GenTex/Insight Biotechnologies, Wembley, UK) and rabbit anti-MAGI3 
antibody (1 μg/ml; Novus/R&D Systems, Abingdon, UK). As controls, the antibodies were substituted with rab-
bit or mouse IgG isotypes (New England Biolabs; 2 μg/ml and 1 µg/ml respectively). Alternatively, the secondary 
antibodies (probes) were in turn omitted and the assay carried out to ensure the specificity (Supplementary 
Fig. 1). The cells were washed three times with PBS and PLA performed according to the manufacturer’s instruc-
tions. The cells were stained with DAPI (2 μg/ml) and Phalloidin-FITC (2 µg/ml). Images were acquired using a 
Zeiss Axio Vert.A1 inverted fluorescence microscope with a × 40 magnification (Carl Zeiss Ltd, Welwyn Garden 
City, UK). The number of red fluorescent events and nuclei were determined using ImageJ, in 10 fields of view 
from each assay.
Co-immunoprecipitation of proteins. Cells were lysed in PhosphoSafe Extraction Reagent (Sigma) con-
taining protease inhibitor cocktail and cell debris removed by centrifugation. MAGI2 protein was immunopre-
cipitated from cell lysates using the anti-MAGI2 (C3; 4 µg) antibody. To ensure specificity, a rabbit IgG isotype 
(4 µg) was also included as well as an additional control without any antibody. The samples were incubated at 
4  °C overnight with gentle shaking. Pureproteome protein A-magnetic beads (10  µl) (Merck-Millipore) was 
added to all samples and controls and incubated at 4 °C for 90 min60. The tubes were then placed in a magnetic 
stand and the supernatant removed, washed five times with PBST (1 ml) and the samples denatured in SDS-
PAGE loading buffer (70 µl) (Sigma). Samples were then separated by SDS-PAGE, transferred to nitrocellulose 
membranes and blocked. The membranes were probed with a mouse anti-PTEN antibody (217702), as well as a 
rabbit anti-MAGI2 antibody and then developed as described above.
Statistical analysis. All data represent the calculated mean values from the number of experiments stated 
in each figure legend ± the calculated standard error of the mean. Statistical analysis was carried out using the 
Statistical Package for the Social Sciences (SPSS Inc. Chicago, USA). Significance was determined using one-way 
ANOVA (analysis of variance) and Tukey’s honesty significance test or where appropriate, by paired t-test.
Results
Assessment of the expression of PTEN in the cells lines. While no PTEN deletions/mutations have 
been reported for any of the cell lines used in this study, this possibility cannot be ruled out. Therefore, in order 
to exclude the expression of aberrant forms of PTEN in the cell lines, the molecular weight of PTEN was exam-
ined by western blot, prior to the study. All the examined cells were shown to express differing amounts of PTEN 
with an approximate molecular weight of 54 kDa (Fig. 1A, Supplementary Fig. 2), although point mutations of 
PTEN cannot be ruled out.
Exposure of cells to TF or PAR2-AP activates PTEN and reduces Akt activity. De-phosphoryl-
ation of PTEN at Ser380, Thr382 and Thr383 is a known step in the activation of  PTEN53. Examination of the 
phosphorylation state of these amino acids in cell lines showed significant decreases in phospho-PTEN (up to 
34%) following a 1 h incubation with rec-TF (65 pg/ml) in MDA-MB-231, MCF-7 and LoVo cells (Fig. 1A,B). 
Activation of PAR2 in cells resulted in the dephosphorylation of PTEN (up to 32%) in MDA-MB-231 and LoVo 
cells but was not significant in the other cells tested (Fig. 1A,C). Incubation of cells with 130 pg/ml rec-TF also 
reduced the phosphorylation of PTEN but was marginally less effective (Fig. 1D) while at 1300 pg/ml no signifi-
cant influence was detected (Fig. 1E). The lower apparent influence on PTEN dephosphorylation, in response to 
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1300 pg/ml rec-TF may be as a consequence of immediate irreparable damage to the cells or detachment of the 
cells since lower remaining cells were available as we have previously  indicated21–23. Therefore to avoid artefacts, 
higher concentrations of TF were not used further in this study. The amounts of PTEN protein as determined by 
the ELISA assay, were not altered by the short-term treatments of the cells (not shown).
PTEN is currently the only established phosphatase capable of hydrolysing Phosphatidyl-Inositol(3,4,5) 
triphosphate (PIP3) to Phosphatidyl-Inositol(4,5) triphosphate (PI4,5P2)61–65. However, to ensure the specific-
ity of the PTEN activity kit used in this study, the PTEN antibody was used to immune-deplete a sample of cell 
lysate along with a control which was immunoprecipitated using an isotype antibody. The PTEN activities of 
the two samples were then examined using the assay. Comparison of the PTEN activities indicated the total 
removal of PI4,5P2 formation potential and therefore confirmed the specificity of the assay kit (Supplementary 
Fig. 3). Measurement of lipid phosphatase activity of PTEN indicated a general increase (up to 33%) in response 
to rec-TF with MDA-MB-231, LoVo and CaCo-2 cells exhibiting the highest increases compared to untreated 
cells (Fig. 2A). PTEN activity was also enhanced in MDA-MB-231, MCF-7 and CaCo-2 cells following PAR2 
activation (up to 34%) (Fig. 2B). These increases in PTEN activity inversely correlated with reductions in Akt 
kinase activity (Pearson correlation = − 0.945; p = 0.003). Akt activity decreased in MDA-MB-231 and CaCo-2 
cells by up to 26% following incubation with rec-TF and up to 23% in response to PAR2 activation (Fig. 2C,D). 
Incubation of cells with rec-TF did not alter the PTEN or Akt activity when measured at earlier time-points. 
Since MDA-MB-231, LoVo and CaCo-2 were found to be most responsive, these cell lines were selected for 
additional studies as outlined below. Both the increase in PTEN activity and the reduction in Akt activity were 
dependent on the activation of PAR2 since the pre-incubation of selected cell lines (MDA-MB-231, LoVo and 
CaCo-2) with a blocking antibody against PAR2 (SAM-11) prevented the effects of additions of TF (Fig. 2E,F).
Prolonged exposure of cells to rec-TF increases cell proliferation. To achieve the sustained activa-
tion of the cells, prolonged incubation of cells was carried out by supplementing the cells with rec-TF (65 pg/ml) 
on day 0, 2 and 4. This treatment of cells resulted in increased cell proliferation by day 5 in MDA-MB-231 (10%), 
LoVo cells (24%) (Fig. 3A,B) and by day 4 in CaCo-2 cells (26%; Fig. 3C). Furthermore, exposure of cells to rec-
TF reduced the level of cellular PTEN antigen in MDA-MB-231 (20%), LoVo (18%) and CaCo-2 (10%) cells by 
the fifth day, compared to equivalent untreated samples (Fig. 4A). However, PTEN mRNA levels remained con-
stant throughout the treatments (Supplementary Figure 4). Prolonged exposure of cells to rec-TF also resulted 
in the enhancement of Akt activity in MDA-MB-231 (9%) and LoVo (29%) but was not significant in CaCo-2 
cells (Fig. 4B). In a similar set of experiments, the MDA-MB-231 and LoVo cells were treated with rec-TF for 
14 days. The increases in cell numbers were determined to be 30% and 33% (Fig. 4C), while the level of cellular 
PTEN declined by 30% and 23% respectively (Fig. 4D) compared to untreated cells. However, the enhancements 
in Akt activity remained at 13% and 29% above untreated cells respectively (Fig. 4E) suggesting that such small 
but persistent increases in Akt activity may become a significant factor in the cumulative divergence in the rate 
of cell proliferation, such as those observed in some chronic conditions.
Activation of PAR2 releases PTEN from MAGI complexes. For the subsequent experiments, MDA-
MB-231 and LoVo cells were considered as suitable cell lines for examining the association of PTEN with 
MAGI1-3, using the proximity ligation assay (PLA). However, because of their smaller size and also complica-
tions arising from cell stacking, the analysis of LoVo cells was found to be erroneous and consequently, further 
studies were carried out in MDA-MB-231 cells only.
Since PTEN has been reported to interact with all three MAGI  proteins25,53,66, the association of PTEN 
with the MAGI proteins was examined. Analysis of the non-activated cells using PLA suggest that PTEN is 
mainly associated with MAGI2 and the least amount with MAGI3 (Figs. 5 and 6A). Moreover, the activation of 
cells using PAR2-AP resulted in 22% and 35% reduction in the association of PTEN with MAGI1 and MAGI2 
respectively, but no significant change was observed with MAGI3 (Fig. 6A). Time-course PLA analysis also 
showed a transient decrease in the association of PTEN with MAGI1 and MAGI2 by 20 min post-activation 
with PAR2-AP and then was partially restored by 30 min incubation (Fig. 6B). Western blot analysis confirmed 
Figure 1.  The influence of incubation of cell lines with rec-TF and PAR2-activation on PTEN phosphorylation. 
(A) Cells (MDA-MB-231, MCF-7, T47-D, LoVo, CaCo-2, AsPC-1 and Panc-1) were cultured in the 
recommended media and activated either by the addition of recombinant TF (0–1300 pg/ml) or by incubation 
with PAR2-agonist peptide (PAR2-AP; SLIGKV; 20 µM) and incubated for the durations shown. The cells were 
then lysed in electrophoresis-loading buffer and separated on a 12% (w/v) denaturing polyacrylamide gel. The 
proteins were then transferred to nitrocellulose membrane and blocked with TBST. The membranes were in 
turn probed using a rabbit anti-human phosphoSer382/Thr382/Thr383-PTEN, a polyclonal rabbit anti-human 
PTEN antibody, both diluted 1:2000 (v/v), or a goat anti-human GAPDH polyclonal antibody (V-18), diluted 
1:4000 (v/v) in TBST. The membranes were then washed with TBST and probed with goat anti-rabbit or donkey 
anti-goat alkaline phosphatase-conjugated antibodies as required, diluted 1:4000 (v/v), for 90 min. Bands were 
then visualised using the Western Blue stabilised alkaline phosphatase-substrate and recorded (micrographs 
are representative of 6 independent experiments; due to the number of gels the micrographs are cropped to 
include the main band but also to include at least three marker bands spanning the protein of interest. Full 
micrograph replicates are included in the supplementary material). The ratio of phospho-PTEN:Total PTEN 
were determined in the cell samples treated with (B) rec-TF (65 pg/ml) for 1 h, and (C) PAR2-AP for 30 min 
(n = 6; *p < 0.05 vs. the respective untreated samples). Similarly, the ratios of phospho-PTEN:Total PTEN were 
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the co-immunoprecipitation of PTEN with MAGI2 from non-activated MDA-MB-231 (Fig. 6C,D) and LoVo 
(Fig. 6E,F) cells which decreased by 28% and 33% following the activation of the two cell lines respectively (full 
gels are shown in Supplementary Fig. 5). Treatment of cells with PAR2-AP did not alter the amount of cellular 
MAGI2 in the period of testing (Supplementary Fig. 6). 
Discussion
The signalling properties of TF have been established previously and the ability of the TF to alter the behaviour 
of cells is well documented. Of particular interest is the ability of TF to confer improved survival in cancer cells, 
and a notable mechanism has been the activation of Akt pathway following the association of TF with factor 
 VII11–16. We hypothesised that the response of cells to acute levels of TF such as those found in injury and trauma, 
may differ from the adaptive behaviour of the cells that is observed during longer-term chronic inflammation. 
As discussed above, any deregulation of PTEN is likely to be an important linkage between chronic inflamma-
tion and tumourgenesis. For this reason, we monitored PTEN and Akt activities in seven cancer cell lines in the 
short-term following a single treatment with rec-TF or PAR2-AP, as well as examining the outcome of exposure 
of cells to repeated doses of TF over longer periods.
Figure 2.  The influence of incubation of cell lines with rec-TF and PAR2-activation on PTEN activity and Akt 
inhibition. Cells (2 × 105) were treated with (A) rec-TF (65 pg/ml) for 1 h, or (B) PAR2-AP for 30 min, lysed 
in PhosphoSafe buffer (150 µl) and the lipid-phosphatase activity of PTEN measured using the echelon PTEN 
Activity ELISA kit (n = 3; *p < 0.05 vs. the respective untreated samples). Akt activity was also determined in the 
samples treated with (C) rec-TF or (D) PAR2-AP as above, and measured using the Akt Kinase activity assay 
kit according to manufacturer’s instructions (n = 3; *p < 0.05 vs. the respective untreated samples). Samples of 
MDA-MB-231, LoVo and CaCo-2 cells were pre-incubated with a PAR2 blocking antibody (SAM-11, 20 µg/ml) 
or a control isotype antibody. The cells were treated with recombinant TF and (E) PTEN activity and (F) Akt 
activity measured as above (n = 3; *p < 0.05 vs. the respective control isotype antibody).
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The function of PTEN as a tumour suppressor has been well recognised and its ability to downregulate Akt 
activity through its lipid phosphatase activity has been extensively  studied49–54. There is already an established 
association between PTEN mutation/deregulation and increased TF expression in cancer  cells67,68. It has also 
been suggested that the tumour cells may express ectopic fVIIa, altering the function of  PARs69–71. In addition 
to PAR2 activation, TF may also influence cells directly by interaction with the cell-surface proteins such as 
β1-integrin72,73. In fact, we previously showed the expression of active form fVIIa in MDA-MB-231, MCF-7 
and AsPC-1  cells70,71 and this constitutes an adequate source of factor fVIIa to drive this mechanism. In these 
studies, suppression of the expression of fVIIa or PAR2 in MDA-MB-231 cells using verified siRNA, or blocking 
with respective inhibitory antibodies, disrupted the release of MV and reduced the rate of cell proliferation in 
otherwise untreated cells. This is in agreement with the findings reported by Åberg et al. who have compre-
hensively described the increased cell proliferation, through the activation of Akt pathway, following the sup-
plementation of TF-expressing cells with  fVIIa11–13. In contrast, the outcome of cellular exposure to exogenous 
TF, and the subsequent activation of PAR2 on PTEN function and PTEN protein levels has not previously been 
examined. In our experiments the optimal timescale for the activation of PTEN and Akt as well as dissociation 
of PTEN from MAGI in response PAR2-AP was found to be around 20–30 min and is comparable to other pub-
lished  timescales74–76. It is expected that the activation of PAR2 by treatment with recombinant TF would take a 
similar timescale to that by microvesicles which adds a further 30 min since the TF needs to become incorporated 
into the cell membrane of  cells77. To allow sufficient time for the TF to be incorporated and then for the PAR2 
signalling to activate PTEN and Akt, we incubated the cells with TF for up to 120 min. However, measurements 
carried out at 30 min did not reveal any change in the PTEN phosphorylation change, post-treatment with 
recombinant TF. Our data indicate that either short-term exposure to TF, or the activation of PAR2 can induce 
some level of PTEN de-phosphorylation in cell lines examined (Fig. 1). In keeping with published  studies47, 
de-phosphorylation of PTEN was concurrent with enhanced lipid-phosphatase activity which in our study, was 
also accompanied by reductions in Akt kinase activity. Following injury or trauma, cells may become exposed 
to large quantities of TF together with the activation PAR2 by coagulation proteases. Therefore, as a possible 
explanation, the lowered Akt activity may be a protective mechanism by which the severely damaged cells are 
prepared for apoptosis and removal, preventing aberrant tissue formation. Moreover, although these effects were 
significant reaching up to 26% in MDA-MB-231 and CaCo-2 cells, the outcome in vivo, is very likely to involve 
other deciding inflammatory factors. In agreement with this, cell numbers were shown to be lower after 24 h 
treatment with TF, compared to the untreated samples in some but not all of the cell lines studied.
Membrane-associated PTEN is stabilised by an interaction with MAGI  proteins78–82, which is mediated 
through the c-terminus of PTEN and the second PDZ domain of MAGI  proteins52. MAGI proteins are mainly 
located at the cell–cell junctions and are involved in the assembly of junction protein  complexes83. Examination of 
MDA-MB-231 cells using PLA indicated the reduced association of PTEN with MAGI proteins in PAR2-activated 
Figure 3.  The influence of long-term treatment of cell lines with rec-TF on cell numbers. Cells (2 × 105) were 
cultured in the recommended media and supplemented every 2 days with rec-TF (65 pg/ml). The number of 
cells in the treated and untreated samples were determined using crystal violet staining (n = 3; *p < 0.05 vs. the 
samples on first day 0) in (A) MDA-MB-231, (B) LoVo and (C) CaCo-2 cell lines.
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cells, and was confirmed by co-immunoprecipitation of PTEN with MAGI2 (Figs. 5 and 6). As far as we are 
aware, the dissociation of PTEN from MAGI proteins in response to PAR2 has not been reported previously. 
This transient release of PTEN was concurrent with a 20% increase in PTEN activity and 18% reduction in Akt 
kinase activity when examined in MDA-MB-231 cells (Fig. 2). This is in line with studies comparing the activity 
of c-terminus truncated PTEN which is incapable of binding to MAGI, to that of the full-length PTEN showing 
approximately 10% increase in the lipid-phosphatase  activity78 together with approximately 17% reduction in 
PI3K  activity79. Therefore, it is conceivable that the dissociation of PTEN from MAGI may transiently increase 
the apparent PTEN activity following injury as a response to disruption of cell junctions. Moreover, exogenous TF 
may form a complex with cell-expressed fVIIa to activate cell-surface PAR2 or alternatively, exogenous TF may 
interact with cell-surface proteins directly. In agreement with the former hypothesis, rec-TF produced a greater 
response in cells with higher levels of PAR2, such as LoVo compared to AsPC-1  cells55. However, the activation 
of PAR2 using the agonist peptide did not always produce the same response as addition of rec-TF and therefore, 
other mechanisms are likely to also be involved. Also, despite the increased PTEN activity, the Akt activity did 
not significantly change in some cells. Therefore, it is possible that in some cell lines a compromised signalling 
mechanism prevents the reduction of Akt or a defective regulatory mechanism may artificially maintain the Akt 
Figure 4.  The influence of long-term treatment of cell lines with rec-TF on cellular PTEN antigen levels and 
Akt activity. Equal number of cells were lysed in PhosphoSafe buffer (150 µl) and (A) the level of PTEN antigen 
measured using a PTEN ELISA kit (n = 5; *p < 0.05 vs. the samples on first day 0). (B) The Akt activity was also 
measured using the Akt Kinase activity assay kit (n = 3; *p < 0.05 vs. the samples on first day 0). Cells (2 × 105) 
were cultured in the recommended media and supplemented every 2 days with rec-TF (65 pg/ml) up to 14 days. 
(C) The number of cells in the treated and untreated samples were determined using crystal violet staining 
(n = 3; *p < 0.05 vs. the samples on first day 0). In addition, cells were lysed in PhosphoSafe buffer and (D) the 
level of PTEN antigen and (E) the Akt kinase activity measured. (n = 3; *p < 0.05 vs. the samples on first day 0).
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activity at higher levels and therefore, alter the cellular behaviour. This was also true on long-term incubation 
of CaCo-2 cells with rec-TF in which, despite a reduction in PTEN (Fig. 4A) the Akt activity did not change 
(Fig. 4B). Therefore, while the signalling pathways arising from PAR2 activation have been characterised, the 
Figure 5.  Analysis of the proximity of PTEN and MAGI1-3 by proximity ligation assay and the influence of 
PAR2 activation. MDA-MB-231 cells  (103) were seeded out into 35 mm-glass based μ-dishes and adapted to 
serum-free medium for 1 h prior to activation. The cells were then incubated with PAR2-AP (20 μM) for up to 
30 min. The proximity between PTEN and MAGI1-3 were examined using a mouse anti-human PTEN (217702) 
diluted 1:100 (v/v) together with a rabbit anti-MAGI1 antibody (H-70; 2 μg/ml), a rabbit anti-MAGI2 antibody 
(1 μg/ml) and a rabbit anti-MAGI3 antibody (1 μg/ml). The cells were then labelled with DAPI (2 μg/ml) and 
Phalloidin-FITC (2 µg/ml). Images were acquired using a Ziess Axio Vert.A1 inverted fluorescence microscope 
with a ×40 magnification (the micrographs are representative of 10 fields of view from 4 independent 
experiments RED = PLA incidences; GREEN = Phalloidin; BLUE = DAPI).
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mechanisms that influence the MAGI proteins need identification and for the present, we have refrained from 
indicating a correlation between the amount of cell surface PAR2 and the magnitude of PTEN regulation.
The de-phosphorylation of PTEN, especially when not protected by MAGI, can lead to further modification 
of the PTEN leading to proteosomal degradation of the  protein53. Therefore, it was envisaged that prolonged 
exposure of cells to TF may progressively activate and then degrade cellular PTEN protein. Measurement of 
PTEN antigen levels, in continuously-treated MDA-MB-231 cells showed a reduction in PTEN antigen but not 
mRNA expression over 5 days, together with increased Akt activity and cell proliferation (Figs. 3 and 4). This 
Figure 6.  Analysis of the interaction of PTEN and MAGI1-3 and the influence of PAR2 activation. 
MDA-MB-231  (103) were seeded out into 35 mm-glass based μ-dishes and adapted to serum-free medium for 
1 h prior to activation. The cells were then incubated with PAR2-AP (20 μM) for up to 30 min and analysed 
by PLA as described in Fig. 5. The number of red fluorescent events and nuclei were determined using ImageJ, 
in 10 fields of view from each assay for (A) the interactions of PTEN with MAGI1-3 in non-activated and at 
20 min post-activation. (B) In addition, the interaction of PTEN and MAGI1 and 2, was measured at intervals 
up to 30 min (n = 3; *p < 0.05 vs. the non-activated sample). MAGI2 was immunoprecipitated from cell lysates 
with an anti-MAGI2 (C3; 4 µg) antibody using protein A-magnetic beads. The MDA-MB-231 lysate samples 
were washed five times with PBST (1 ml) and denatured in SDS-PAGE loading buffer and (C) examined for 
PTEN and MAGI2 by western blot using a mouse anti-PTEN antibody (217702) and a rabbit anti-MAGI2 
antibody. (D) The ratio of the PTEN band densities were normalised against those of MAGI2 in the same 
co-immunprecipitated samples (n = 3; *p < 0.05 vs. the non-activated sample). Similarly, the LoVo lysate samples 
were used to immunoprecipitate MAGI2 and (E) examined for PTEN and MAGI2 by western blot using a 
mouse anti-PTEN antibody (217702) and a rabbit anti-MAGI2 antibody. (F) The ratio of the PTEN band 
densities were normalised against those of MAGI2 in the same co-immunprecipitated samples (n = 3; *p < 0.05 
vs. the non-activated sample). Full micrograph replicates are included in the supplementary material.
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depletion of PTEN together with increased Akt activity suggests a mechanism by which the regulation of cell 
survival, proliferation and apoptosis becomes compromised by prolonged exposure to TF. Low level expression of 
Akt in mice has been shown to alter the tissue morphology and can compound tumour formation and  survival84. 
Therefore, while the increases in Akt activity were significant reaching 29% in LoVo cells, such outcomes are 
likely to become dominant over longer periods of time as observed during chronic inflammatory diseases. 
Similarly, it has been reported that subtle reductions in PTEN protein levels increase the susceptibility of cells 
to tumourgenesis through the activation of the PI3K-Akt  pathway28,85. Therefore, this study suggests that the 
prolonged exposure of cells to TF together with the activation of PAR2 may contribute to tumourgenesis through 
the degradation of PTEN resulting in tumour cell proliferation. Such decreases in PTEN levels have already been 
shown to have implication in clinical settings, with outcomes influencing non-malignant  tumourgenesis35–37, 
 carcinogenesis33,34 as well as the progression of  cancers29–32. This study attempted to decipher the molecular and 
cellular connections between the exposure of TF during inflammatory conditions and the regulation of PTEN 
and Akt activity and therefore an extended discussion of clinical manifestations and influences remains beyond 
the remit of this study.
The disruption of cellular layers often occurs as a consequence of injury which and often results in the expo-
sure of TF and the activation of  coagulation86,87. Under such conditions, it is imperative to make a distinction 
between the severely injured cells and those which may be revived. Since TF is one of the first proteins which 
appears at the site of injury, it may possess the ability to subsequently initiate differing signals in order to direct 
the cells towards apoptosis or proliferation respectively. This study has demonstrated the ability of TF to induce 
PTEN activation in the short term, while prolonged exposure to TF appears to reduce the total cellular PTEN 
protein. This may in turn result in aberrant cell survival and proliferation during disease conditions.
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